Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight Rating

Benzinga · 2d ago
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Overweight rating.